Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Donanemab Discontinuation Timing Using Amyloid PET
jRCTs051260074Recruiting
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of donanemab in Alzheimer's disease (AD), mild cognitive impairment due to Alzheimer's disease and Dementia. Started Jun 2026; status: recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's diseaseDementia
Beyond the preview
Go deeper on jRCTs051260074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051260074.